Trikafta Helps Lung Function in CF Patients with Certain Mutations

Trikafta Helps Lung Function in CF Patients with Certain Mutations

304373

Trikafta Helps Lung Function in CF Patients with Certain Mutations

The triple-combination therapy Trikafta significantly improved lung function and life quality in a global Phase 3 trial that enrolled people with cystic fibrosis (CF) caused by one F508del mutation, and one gating mutation or one residual function mutation, in the CFTR gene. Data from the trial were reported last year by Vertex Pharmaceuticals, which markets Trikafta. Now, the findings have undergone peer review and been published in the New England Journal of Medicine, in the…

You must be logged in to read/download the full post.